Home
HelpTest ID ADMA Asymmetric Dimethylarginine, Plasma
Useful For
An adjunct to other risk markers for assessing an individual's likelihood of future coronary events, in patients with coronary heart disease, type-II diabetes mellitus, or kidney disease
Method Name
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Asymmetric Dimethyl Arginine, PSpecimen Type
Plasma EDTACollection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Fasting-overnight (12 hours)
Forms: If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/cardiovascular-request-form.pdf).
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Plasma EDTA | Frozen (preferred) | |
| Ambient | 7 days | |
Clinical Information
Asymmetric dimethylarginine (ADMA) is an independent risk factor for coronary heart disease.(1) ADMA inhibits nitric oxide (NO) synthesis and is elevated in diseases related to endothelial dysfunction including hypertension, hyperlipidemia, and type-II diabetes mellitus. Elevation in ADMA and subsequent NO synthesis inhibition leads to vasoconstriction, reduced peripheral blood flow, and reduced cardiac output.
Elevated plasma ADMA confers a 4- to 6-fold increased risk of subsequent cardiovascular events or mortality among patients with acute coronary syndrome (2), unstable angina (3), type-II diabetes mellitus (4), end-stage renal disease (5), and coronary heart disease.(6) Among patients with coronary heart disease, baseline ADMA remained a significant risk factor of adverse events even after adjusting for LDL-C, HDL-C, triglycerides, creatinine and high sensitivity C–reactive protein.
Plasma ADMA concentrations are lowered by rosuvastatin and atorvastatin, but not simvastatin in patients with hypercholesterolemia.(7) Addition of vildagliptin (Galvus) to metformin significantly reduced ADMA concentrations among patients with type-II diabetes mellitus.(8)
Reference Values
<18 years: not established
≥18 years: 63-137 ng/mL
Cautions
The test has no value in patients who smoke. Elevated values should not be used to diagnose the presence of disease or events.
Day(s) Performed
Thursday; 11 a.m.
Report Available
2 daysPerforming Laboratory
Mayo Medical Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
82542